Reestablishment of Active Immunity against HBV Graft Reinfection after Liver Transplantation for HBV-Related End Stage Liver Disease

Table 4

Characteristics of the 4 HBV-reinfected patients.

(a)

Case	Subtype of HBV	Mutation in the region of HBV polymers	Mutation in the region of HBV gene S	Mutation in the region of HBV gene PreS/S	BCP mutation			HBV DNA before OLT (copies/mL)	Antiviral agent before OLT
					A1762T	G1764A	G1896A
1	C1	—	P120PQ, M133MT, G145R	—	Negative	Negative	Negative	negative	LAM
2	C2	—	—	—	Negative	Negative	Negative		LAM
3	B2	N236T	Q129R	PreS2 TGTACTTTC (46–54 nt) deletion	Positive	Positive	Negative	negative	ETV
4	B2	—	G145R	—	Negative	Negative	Negative		ADV

(b)

Case	Vaccine type	Number of doses for reestablishment of immunity	Antiviral agent after OLT	Interval of time between withdrawal of nucleoside analogues and HBV reinfection (month)	HBV DNA at the time of HBV reinfection (copies/mL)	Current antiviral agent	Current HbsAg	Current HBV DNA (copies/mL)
1	Twinrix	5	ADV	12		TDF	Positive	Negative
2	Twinrix	6	ADV	6		ETV	Positive	Negative
3	Twinrix	10	ETV	16	<	ETV	Negative	Negative
4	Engerix-B	6	ADV	23		TDF	Positive